🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Shares

Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive

Published 06/07/2023, 20:48
Updated 06/07/2023, 22:10
© Reuters.  Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive

Benzinga - JMP Securities has increased the price target for Protagonist Therapeutics Inc (NASDAQ: PTGX) from $28 to $35, with a Market Outperform rating.

Protagonist Therapeutics announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult patients with moderate-to-severe plaque psoriasis presented at World Congress of Dermatology in Singapore.

JMP analyst says the detailed Phase 2b data support JNJ-2113 as the most efficacious oral agent in development for psoriasis.

It notes that JNJ-2113 led to PASI response rates better than any other oral agent approved or in development for psoriasis with a clean safety profile.

The shares fell as the data fell short of injectables. But the analyst says the full data shows ‘2113 as the only oral IL-23R antagonist in development and has a unique position backed by Phase 2 data better than any oral out there.

The shares have not fully recovered, attributed to:

  • The best ‘2113 responses were observed with its twice-daily dose.
  • Data from Ventyx Biosciences Inc’s (NASDAQ: VTYX) oral TYK2 inhibitor VTX958 are coming in 4Q23, and some investors think this candidate could take the pole position as the best oral in development.
JMP writes that given the size of the psoriasis market and lack of good oral options, multiple agents can potentially have commercial success.

Price Action: PTGX shares are up 0.98% at $23.62 on the last check Thursday.

Latest Ratings for PTGX

DateFirmActionFromTo
Feb 2022BTIGInitiates Coverage OnBuy
Nov 2021JMP SecuritiesMaintainsMarket Outperform
Oct 2021JMP SecuritiesMaintainsMarket Outperform
View More Analyst Ratings for PTGX

View the Latest Analyst Ratings

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.